

FIG. 2





FIG. 3

Reactivity of MAb B6.1 against
PS76-carrier protein conjugates








FIG. 5



Dots 1, 2 - normal mouse serum; Dots 3-10 - serum from peptide-immunized mice; Odd dots - IgG detection; Even - IgM detection

FIG. 6

Immunization with peptide mimotopes induces anti-Candida carbohydrate antibodies in mice



Absorbance = $OD_{490nm} (Ab + 2ME \text{ extract}) - OD_{490nm} (Ab + \text{irrelevant CHO})$

Microtiter plate wells were coated with 2ME extract or an irrelevant carbohydrate. Mice were immunized with synthetic peptide, branched synthetic peptide, peptide carrier protein conjugates, or phage-displayed peptide mimotopes.

FIG. 7

Gene 3 protein of phage clone PS76




FIG. 8B




FIG. 8A




FIG. 9A




FIG. 9B






FIG. 10




FIG. 11

Disseminated Candidias By Survival Time
measurements. Therapeutic effect of MAb B6.1 on candidate
injected mice (one hour infection)




FIG. 12




FIG. 14





FIG. 15

Effect of active immunization with L-adhesion to mice
against vulvovaginal candidiasis




L = liposome

L02ME = liposome - 2ME vaccine prep. Animals received 0.2 ml i.v. (178µg 2ME in 0.2ml) weekly for 5 weeks.

Estriadiol was given subcu, 72 h later *C. albica* (5×10^5) given intravaginally, 48h after infection vaginal cfu determined.

Proposed structure of the phosphomannan complex (PMC) - in this case, n-linkage to cell wall protein is shown.



acid stable

C. albicans NIH B-792 strain

Shibata, et al. J. Biol. Chem 270: 1113-1995

FIG. 17




FIG. 19





FIG. 20



2 - dNMR of B6.1 epitope


[illegible]

Country	1950	1955	1960	1965	1970	1975	1980	1985	1990	1995	2000	2005	2010	2015	2020	2025	2030	2035	2040	2045	2050
Japan	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27
Germany	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30
France	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32
Italy	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33
Spain	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34
Sweden	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35
United Kingdom	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36
United States	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37
Canada	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38
Belgium	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39
Netherlands	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40
Australia	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41
South Korea	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42
India	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43
China	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44
Indonesia	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45
Brazil	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46
Mexico	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47
Argentina	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48
Colombia	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49
Venezuela	30	31	32	33	34	35	36	37	38	39	40										



****Mice were intravaginally infected with *Candida albicans* (5×10^5 /mouse) 1 hr before i.v. vaccine treatment. Seven days after the infection, vagina areas were collected, and cfu in the areas were measured.**

FIG. 22




*Animals were infected with *C. albicans* one hr before antibody treatment.

T=0 5x10⁵/10μl lvg.
T=1h MAb B6.1 30μl undil 1280, 3.5 mg/ml
T=24h MAb B6.1 10μl
T=48h cfc



FIG. 23

Therapeutic effect of MAb B6.1 & B6 on mice*
against vulvovaginal candidiasis.



*Animals were infected with *C. albicans* four hrs before first antibody treatment.

T=0	Infect 5x10 ⁵ ivg	<u>MAb B6.1</u>	<u>MAb B6</u>
T=4h	MAb 30μl ivg	1280, 3.5mg/ml	640, 3.5mg/ml
T=24h	MAb 10μl		
T=48h	cfu		

FIG. 24

Purification of 2ME-BSA by a sephacryl-S-300 column




FIG. 25

Purification of 2ME-BSA by a sephacryl-S-300 column

